Maky Zanganeh’s Astonishing Journey: From Revolution Survivor to America’s $1.5 Billion Biotech Powerhouse Maky Zanganeh’s rise from war-torn Tehran to biotech billionaire is fueling groundbreaking cancer innovation in 2025. Get…
AI Drug Revolution: Insilico Medicine’s New Discovery Could Transform Lung Disease Treatment Globally Insilico Medicine's AI-powered drug for lung disease shows promising clinical results, signaling a major leap for biotech…
Wacker Biotech and RNAV8 Bio have joined forces to revolutionize mRNA engineering, transforming treatments for genetic and common diseases. Wacker Biotech specializes in producing high-quality mRNA and formulating lipid nanoparticles…
Wacker Biotech and RNAV8 Bio have formed a strategic partnership to advance mRNA therapeutics. Wacker Biotech brings its expertise in microbial fermentation, processing up to 650 liters of material, to…
Wacker Biotech and RNAV8 Bio have partnered to advance mRNA therapeutics, aiming to revolutionize treatment landscapes for various diseases. Wacker Biotech specializes in microbial fermentation, producing high-quality pharmaceutical proteins and…
Abzena is at the forefront of innovation in bioconjugation and complex biologics, transforming drug development. Led by Dave Williamson, a former soldier turned Chief Information Officer, the company leverages big…
Wacker Biotech and RNAV8 Bio are collaborating to revolutionize mRNA-based therapies. Wacker Biotech brings expertise in pDNA/mRNA manufacturing and lipid nanoparticle (LNP) formulation. RNAV8 Bio specializes in optimizing noncoding mRNA…
Wacker Biotech and RNAV8 Bio partner to advance mRNA-based therapies, leveraging expertise in pDNA, mRNA production, and LNP formulation. RNAV8 Bio's innovative approach to mRNA engineering optimizes untranslated regions (UTRs)…
A groundbreaking partnership between Wacker Biotech and RNAV8 Bio aims to revolutionize mRNA-based therapies in biopharma. This collaboration combines Wacker Biotech's manufacturing prowess with RNAV8 Bio's advanced mRNA engineering techniques.…
Neurona Therapeutics is advancing allogeneic cell therapy for drug-resistant mesial temporal lobe epilepsy (MTLE) with its promising NRTX-1001 therapy. Supported by a $102 million financing round, Neurona is navigating the…